6-Hour Program

See Credit Details Below

Overview

Why you should attend

This year’s program is totally new! Pharmaceutical and biotech patent law is an important and rapidly changing practice area and the program is designed to give you the information you need to maintain your practice edge, concentrating on new developments from 2011 and placing them in the context of constantly evolving areas of the law.

Technological innovation, Federal Circuit appellate oversight, and Supreme Court decisions continue to drive significant changes in the law. Several different perspectives on many of the most pressing issues will be offered from very experienced practitioners.

Do not miss this opportunity to fully understand the impact of new appellate decisions on your pharmaceutical and biotechnology patent practice.

What you will learn

  • The impact of the U.S. Supreme Court’s March 20, 2012 decision in Mayo Collaborative Services v. Prometheus Laboratories, Inc.
  • The effect of the American Invents Act on pharma and biotech patent practice
  • Top pharmaceutical and biotech decisions from 2011
  • Recent Supreme Court decisions and its continued focus on patent law
  • Continued developments in the law of inequitable conduct and its affect on pharmaceutical and biotech patents
  • The Federal Circuit’s new standard for determining inequitable conduct and its implications for prosecution and litigation
  • Section 101 developments on patentable subject matter
  • Litigating patent cases - a view from the Federal bench

Who should attend

Attorneys, whether in-house counsel or practicing at law firms, who are responsible for pharmaceutical and biotech patent prosecution, patent litigation, and patent transactions and strategies, will benefit from attending this program.

Credit Details